Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac ® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a single dose Data establishes preclinical proof of principle for treatment of Hemophilia A across all